Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | F10 | P00742 | 11/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | CALML3 | P27482 | 1/20 | 0.49 |
| ▸ | SDHA | P31040 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5214711 | 0.85 | MAOA (0.62) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL7563346 | 0.85 | MAOA (0.56) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL7526695 | 0.85 | MAOA (0.52) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL5215613 | 0.83 | MAOA (0.58) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL6403024 | 0.81 | MAOA (0.62) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL6403027 | 0.81 | MAOA (0.62) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL5217995 | 0.81 | MAOA (0.48) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL5217988 | 0.81 | MAOA (0.50) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL4883475 | 0.80 | MAOA (0.59) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL14197149 | 0.80 | MAOA (0.59) | MAOAMAOBF10LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467992-B1 | ANTIMICROBIAL DIHYDROTHIAZINE AND DIHYDROTHIOPYRAN OXAZOLIDINONES | PHARMACIA & UPJOHN CO LLC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7101874-B2 | Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones | PHARMACIA AND UPJOHN COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050143376-A1 | Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones | GORDEEV MIKHAIL F (US) | 2005-06-30 | — | — | US | disclosed |
| US-6884813-B2 | Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones | PHARMACIA & UPJOHN COMPANY (US) | 2005-04-26 | — | — | US | disclosed |
| EP-1467992-A1 | ANTIMICROBIAL DIHYDROTHIAZINE AND DIHYDROTHIOPYRAN OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030232812-A1 | Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones | PHARMACIA & UPJOHN COMPANY | 2003-12-18 | — | — | US | disclosed |
| WO-2003062231-A1 | ANTIMICROBIAL DIHYDROTHIAZINE AND DIHYDROTHIOPYRAN OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2002-09-19 | — | — | US | disclosed |
| US-6365751-B1 | ACTIVE AGAINST GRAM-POSITIVE BACTERIA, IN PARTICULAR, AGAINST STRAINS RESISTANT TO VANCOMYCIN, AMINOGLYCOSIDES AND PENCILLINS AND DERIVATIVES; NONTOXIC | ZENECA LTD. (GB) | 2002-04-02 | — | — | US | disclosed |
| US-6271383-B1 | USEFUL ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS; IN PARTICULAR, AGAINST VARIOUS STRAINS EXHIBITING RESISTANCE TO VANCOMYCIN AND AGAINST E. FAECIUM STRAINS RESISTANT TO BOTH AMINOGLYCOSIDES AND CLINICALLY USED BETA-LACTAMS. | ZENECA LIMITED (GB) | 2001-08-07 | — | — | US | disclosed |
| EP-0882042-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | AstraZeneca UK Limited (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997030995-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143376-A1 | Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones | DHX35, DHX15, OXA1L | MAOA 3852/4885MAOB 3530/4885F10 1666/4885 |
| US-20030232812-A1 | Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones | DHX35, ZYX, DHX15 | MAOA 3803/4885MAOB 3725/4885F10 1689/4885 |
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | OXA1L, POLN, MRPL21 | MAOA 2791/4885MAOB 2698/4885F10 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.